Binding of BIM to MCL-1 increases under BCL-2 pharmacological inhibition in acute myeloid leukemia cells, thus emphasizing the ability of MCL-1 to take over pro-apoptotics released by other anti-apoptotic proteins26. Here, BCL2L11 is linked to acute myeloid leukemia.